Comparative Pharmacology
Head-to-head clinical analysis: DILOR versus DILOR 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR versus DILOR 400.
DILOR vs DILOR-400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in neonates, elderly, and patients with hepatic or cardiac dysfunction. Theophylline is a narrow therapeutic index drug; half-life dictates dosing frequency and need for therapeutic drug monitoring.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Renal: approximately 50% unchanged drug; biliary/fecal: minimal (less than 10%). The remainder undergoes hepatic metabolism.
Renal (70% unchanged), hepatic metabolism (30%)
Category C
Category C
Bronchodilator
Bronchodilator